AbbVie and FutureGen Biopharmaceutical Co., Ltd. have entered into a license agreement to develop FG-M701, a next-generation TL1A antibody for the treatment of IBD. FG-M701 is a fully human monoclonal antibody targeting TL1A, a target in IBD. The antibody is engineered
AbbVie, a global biopharmaceutical company, announced on February 12, 2024, that it has completed its acquisition of ImmunoGen. This acquisition includes ImmunoGen’s flagship antibody-drug conjugate (ADC) ELAHERE® (mirvetuximab soravtansine-gynx), a treatment for folate receptor-alpha (FRα) positive platinum-resistant ovarian cancer (PROC). The
AbbVie has announced a significant investment of $223 million in a new biologics manufacturing facility in Singapore. The expansion will add more than 100 jobs and new biologics manufacturing capacity to AbbVie’s global network. The construction will commence immediately with
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
